Can Vaginal Baclofen Relieve Severe Pelvic Muscle Pain?

Chronic pelvic pain presents a complex challenge for clinicians and patients alike. Many affected individuals suffer from pelvic floor muscle dysfunction, yet targeted therapies remain scarce. A recent randomized controlled trial evaluated whether baclofen vaginal suppositories offer relief for this debilitating condition. This clinical breakthrough brings targeted local therapy into sharper focus.

Efficacy of Baclofen Vaginal Suppositories

Researchers evaluated thirty-seven women with severe pelvic muscle tenderness. Specifically, participants exhibited at least forty millimetres of pain on a visual analogue scale. Clinicians randomized them to receive either twenty milligrams of nightly baclofen or a matched placebo. After eight weeks, the treatment group showed substantial clinical improvement. In fact, patients using baclofen achieved a median reduction of 33.5 millimetres on standardized examination. Meanwhile, the placebo group experienced only a 7.2 millimetre reduction. Furthermore, patient-reported overall daily pain dropped significantly among baclofen users.

Clinical Mechanisms and Safety Profile

Pelvic floor hypertonicity often drives persistent distress in female pelvic pain syndromes. Consequently, targeting local neuromuscular pathways provides a rational therapeutic strategy. Oral skeletal muscle relaxants often cause systemic sedation and dizziness. In contrast, local vaginal administration delivers targeted drug concentrations directly to pelvic structures. The trial confirmed an excellent safety profile for this route. In addition, adverse events remained rare and mild throughout the eight-week intervention. Therefore, local delivery avoids the dose-limiting central adverse effects of oral baclofen.

Implications for Gynaecologic Practice

Physicians frequently encounter patients whose pelvic pain resists standard analgesics. As a result, many women undergo prolonged, ineffective oral regimens. Standardized pelvic floor examinations can identify hypertonic muscle trigger points. Hence, clinicians should palpate the levator ani and obturator internus muscles during initial assessments. When localized spasm is present, compounded vaginal muscle relaxants represent a viable intervention. Moreover, these suppositories integrate seamlessly into comprehensive multidisciplinary management protocols. Clinicians can readily combine them with targeted pelvic floor physical therapy.

Frequently Asked Questions

Q1: What dose of baclofen was evaluated in the clinical trial?

The trial evaluated a twenty-milligram compounded baclofen vaginal suppository inserted once daily at bedtime over an eight-week treatment course.

Q2: How does vaginal baclofen differ from oral muscle relaxants?

Vaginal administration delivers the muscle relaxant directly to hypertonic pelvic muscles. Thus, it minimizes systemic absorption and avoids severe sedation.

Q3: Which patients benefit most from this treatment approach?

Women with chronic pelvic pain exhibiting severe tenderness during palpation of the levator ani or obturator internus muscles benefit most.

References

1. Rothenberger RW et al. Baclofen Vaginal Suppositories in Chronic Pelvic Pain: a Randomized, Double-Blind, Placebo Controlled Trial. Am J Obstet Gynecol. 2026 Nov 05. doi: undefined. PMID: 42988098.
2. Horne AW, Vincent K, Hewitt CA, et al. Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2020;396(10255):909-917.
3. Engeler D, Baranowski AP, Berghmans B, et al. EAU Guidelines on Chronic Pelvic Pain. European Association of Urology; 2024.